Fundraising Fox

Aktis Oncology

NASDAQ: AKTS

Boston, US · Founded 2020 · Delaware corporation · 8 known investors

aktisoncology.com ↗

Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.

BiotechHealthtechMedical Devicesin /aktis-oncology

Founders & leadership

TF
Todd FoleyCo-founder and Chairman
PB
Patrick BaeuerleCo-founder & Advisor
SR
Shulamit Ron-BiggerExecutive Officer
HS
Helen S. KimDirector
ON
Oleg NodelmanDirector
AL
Andrew LevinDirector
MR
Matthew RodenExecutive Officer, Director
KH
Ken HerrmannDirector
LS
Lloyd SegalDirector

Investors · 8

Andreessen HorowitzMenlo Park · $500K – $50M
EcoR1 CapitalSan Franciscovia Oleg Nodelman · board
MPM BioImpactBoston · $1M – $15M
MPM Capital
MRL Ventures FundCambridge · $25M
RA CapitalBoston
TCG CrossoverPalo Alto
Vida VenturesLos Angelesvia Helen S. Kim · board

Reported raises · per SEC filings

Form D private placements
▶$175MraisedOct 2024 · 39 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Helen S. KimDirector
  • Shulamit Ron-BiggerExecutive Officer
  • Ken HerrmannDirector
  • Lloyd SegalDirector
  • Oleg NodelmanDirector
  • Andrew LevinDirector
  • Matthew RodenExecutive Officer, Director
  • Todd FoleyDirector
Offering amount
$175M
Amount sold
$175M
First sale
Sep 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news